Threshold Pharmaceuticals, Inc (THLD): Opiniones

En el HIPOTETICO caso qur J. Wilfred se largara entraria inmediatamente otro tipo nombrado a dedo por Three Arch Partners. Es prescindible. No es Selick que como CEO es la imagen de la compañia y ya serian palabras mayores.

a principios de junio se vendieron MUCHISIMAS MAS y no paso nada.

¿Nos vamos a los 5$?

Un saludo

muy poco volumen tenemos

La sigo viendo en buen forma.
Si sigue entrando sangre azul ( que reconozca el konkorde ), y MACD se gira al alza y el precio se mueve en rango un tanto estrecho ... yo lo llamo "aquí están acumulando o cerrando cortos"

Se supone que estan terminando ya fase 2 de Astrocitoma pero como no hay leaks con esta gente no se entera uno de nada hasta que lo dicen:

http://clinicaltrials.gov/ct2/show/NCT01403610?term=th-302&rank=4

le esta entrando pasta,

podían hacernos una tipo cldx pcyc infi, no estaría mal ehh

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors (Fase 1/2)

Estimated Enrollment:90
Study Start Date:August 2008
Estimated Study Completion Date:July 2012
Estimated Primary Completion Date:July 2012 (Final data collection date for primary outcome measure)

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery (Fase 1/2)

Estimated Enrollment:48
Study Start Date:May 2012
Estimated Primary Completion Date:January 2014 (Final data collection date for primary outcome measure)

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias (Fase 1)
Estimated Enrollment:40
Study Start Date:June 2010
Estimated Study Completion Date:June 2013
Estimated Primary Completion Date:June 2013 (Final data collection date for primary outcome measure)

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (TH-CR-410) (Fase 1)

Estimated Enrollment:58
Study Start Date:June 2011
Estimated Study Completion Date:June 2013
Estimated Primary Completion Date:June 2013 (Final data collection date for primary outcome measure)

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma (Fase 1/2)

estimated Enrollment:60
Study Start Date:February 2012
Estimated Study Completion Date:January 2014
Estimated Primary Completion Date:January 2014 (Final data collection date for primary outcome measure)